• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Mer­ck vet Thomas Can­nell takes the reins at Sesen Bio; Post-tur­bu­lence, Rock­well Med­ical ap­points new CEO

7 years ago
Peer Review

Trump ad­min­is­tra­tion sinks teeth in­to par­ing down drug prices, on 5 key points

7 years ago
Pharma

Pfiz­er, No­var­tis jump in­to an $84M de­vel­op­ment round for UK can­cer drug stars at Ar­tios

7 years ago
Financing

Chi­na reg­u­la­tors of­fer VIP treat­ment for 48 over­seas drugs they're ready to hus­tle up with ac­cel­er­at­ed re­views

7 years ago
China
Pharma

In back-to-back tri­al dis­as­ters, Gem­phire now says it shut­tered a tri­al af­ter see­ing pa­tients' fat­ty liv­er dis­ease ...

7 years ago
R&D

Astel­las grabs a biotech tod­dler in $109M buy­out deal for a glau­co­ma gene ther­a­py pro­gram

7 years ago
Deals
Cell/Gene Tx

Lig­and ac­quires Ver­nalis at bar­gain price of $43M; Pfiz­er, No­vo back $60M round for dwarfism biotech

7 years ago
News Briefing

Once a multi­bil­lion dol­lar com­pa­ny, Ova­Science ends a pen­ny­s­tock ve­hi­cle for Mil­len­do's re­verse merg­er

7 years ago
Deals

Bio­gen's high-stakes Alzheimer's gam­ble is be­ing roast­ed by the ex­perts. Is the amy­loid be­ta the­o­ry dead?

7 years ago
R&D
Pharma

That BLA lit­tle Am­pio promised? That’s not go­ing any­where as FDA slap-down trig­gers an ug­ly rout

7 years ago
R&D

Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

7 years ago
Financing
China

FDA ap­proves first gener­ic drug to re­ceive CGT des­ig­na­tion

7 years ago
Pharma

Sarep­ta all-in on gene ther­a­py pipeline, adding 3 CNS treat­ments in $30M Lac­er­ta deal

7 years ago
Pharma

Tap­ping Chi­nese in­vestors, Apex­i­gen clos­es $73M for 8 tri­als in I/O

7 years ago
Financing
Startups

Ky­owa Kirin gets some added love from the FDA, win­ning their sec­ond drug OK in 4 months

7 years ago
Pharma

Paratek clears one last big hur­dle on the way to an FDA mar­ket­ing de­ci­sion for an­tibi­ot­ic

7 years ago
R&D

In­sid­er trad­ing in Wash­ing­ton: NY Con­gress­man in­dict­ed for shar­ing in­side biotech tips ahead of mas­sive tri­al fail­ure

7 years ago
People

BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

7 years ago
Financing
China

Cell­tri­on re­ceives Form 483 for trou­bled Ko­re­an site

7 years ago
Pharma

Prof­its sink­ing, My­lan looks to strate­gic al­ter­na­tives; No­vo posts de­press­ing Q2

7 years ago
News Briefing

Re­genxBio ral­ly fades fast af­ter biotech re­ports set­backs, hos­pi­tal­iza­tion in gene ther­a­py study

7 years ago
R&D

First-in-hu­man stud­ies in sight, SQZ's cell ther­a­py tech wins over a di­verse group of in­vestors in $72M round

7 years ago
R&D
Discovery

Third Rock­'s Am­bys hauls $140M for liv­er dis­ease, ink­ing Take­da deal ahead of launch

7 years ago
Financing
Startups

Sam­sung out­lines block­buster in­vest­ment plan for bio­phar­ma­ceu­ti­cals, part of a $22B play on next-gen tech

7 years ago
Financing
AI
First page Previous page 1005100610071008100910101011 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.